Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Neoadjuvant Trial of Docetaxel, Carboplatin, and Capecitabine in Early Stage Locally Advanced and Inflammatory Breast Cancer
NCT00251329Phase 2Unknown
- Sponsor
- SWOG Cancer Research Network
- Start
- May 2003
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of docetaxel, carboplatin and capecitabine in breast cancer, sponsored by SWOG Cancer Research Network. Primary endpoint: Pathological Complete Response Rate in the Breast. Status: unknown.
02
Drugs
docetaxelcarboplatincapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00251329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251329.